Back to Search
ROBERT ORLOWSKI, MD
MD
Hematology & Oncology Physician
NPI: 1336209956IndividualAccepts Medicare
Specialties, Licenses & Credentials
Hematology & Oncology PhysicianPrimary
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
M8229(TX)
Education
YALE UNIVERSITY SCHOOL OF MEDICINE
Class of 1991
Research & Publications (20)
Proteasome inhibitors in cancer therapy: lessons from the first decade.
PMID 18347166·Clin Cancer Res·2008
6-review
Role of combination bortezomib and pegylated liposomal doxorubicin in the management of relapsed and/or refractory multiple myeloma.
PMID 19436606·Ther Clin Risk Manag·2009
8-other
Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors.
PMID 19050304·Blood·2009
8-other
International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation.
PMID 19494840·Leukemia·2009
6-review
Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death.
PMID 19344406·Br J Haematol·2009
4-observational
Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: efficacy and safety in patients with renal function impairment.
PMID 19064400·Clin Lymphoma Myeloma·2008
8-other
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
PMID 18094721·Leukemia·2008
6-review
Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy.
PMID 18300257·Cancer·2008
3-trial
Targeting the p27 E3 ligase SCF(Skp2) results in p27- and Skp2-mediated cell-cycle arrest and activation of autophagy.
PMID 18305219·Blood·2008
8-other
A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors.
PMID 18327587·Cancer Chemother Pharmacol·2008
3-trial
Altered editing in cyclic nucleotide phosphodiesterase 8A1 gene transcripts of systemic lupus erythematosus T lymphocytes.
PMID 18462347·Immunology·2008
8-other
Inhibition of the p53 E3 ligase HDM-2 induces apoptosis and DNA damage--independent p53 phosphorylation in mantle cell lymphoma.
PMID 18765533·Clin Cancer Res·2008
8-other
Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma.
PMID 17975159·Clin Cancer Res·2007
8-other
Mitogen-activated protein kinase phosphatase-1 is a mediator of breast cancer chemoresistance.
PMID 17483361·Cancer Res·2007
8-other
American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma.
PMID 17515569·J Clin Oncol·2007
6-review
Emerging data on the use of anthracyclines in combination with bortezomib in multiple myeloma.
PMID 17562254·Clin Lymphoma Myeloma·2007
6-review
Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma.
PMID 17591945·Blood·2007
4-observational
Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.
PMID 17679727·J Clin Oncol·2007
3-trial
A practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedings.
PMID 18000495·Clin Adv Hematol Oncol·2007
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1515 HOLCOMBE BLVD UNIT 429
HOUSTON, TX 77030 - Phone
- (713) 792-2860
Quick Facts
- NPI
- 1336209956
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 35
- Publications
- 20
Are you this provider?
Claim Your Profile